News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Isis Pharmaceuticals, Inc. Discusses its New ISIS 301012 Phase 2 Clinical Data Presented at the DALM Symposium
October 1, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CARLSBAD, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS - News) announces the following webcast:
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Insights
The future of pain relief: Exploring opioid alternatives
July 16, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Lung cancer
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
July 15, 2026
·
2 min read
·
Michael Gibney
Antibody-drug conjugate
Pfizer scraps Seagen-developed ADC for solid tumors
July 15, 2026
·
1 min read
·
Gabrielle Masson
Podcast
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
July 15, 2026
·
1 min read
·
Jef Akst
